Rapamycin (sirolimus) inhibits mTORC1 — the nutrient-sensing kinase complex that integrates signals from amino acids, insulin, growth factors, and energy status to regulate cellular growth, protein synthesis, autophagy, and senescent cell accumulation. When mTORC1 is active (nutrients plentiful, growth factor signaling high), cells grow and divide; autophagy is suppressed; senescent cell clearance slows. When mTORC1 is inhibited — by rapamycin, caloric restriction, low insulin, or low amino acid availability — cells shift into a maintenance and repair mode: autophagy increases, protein quality control improves, cellular senescence is reduced. This maintenance mode is associated with slower biological aging in every model organism studied.
Rapamycin is the most powerful and reproducible pharmacological life extension tool in mammalian models, extending median lifespan 10–23% in mice across multiple independent studies. The question for humans is whether: (1) the mouse data translates to human biology, (2) the safety profile at low intermittent doses is acceptable for healthy people, and (3) the immune benefits seen in Mannick's trials represent genuine rejuvenation. Off-label rapamycin use for longevity is growing among physicians and longevity-focused individuals — Peter Attia, David Sinclair, and other longevity physicians have publicly discussed their use. It is not an over-the-counter supplement and requires a prescription and physician supervision.
| mTORC1 — Active State (Nutrients High) | mTORC1 — Inhibited State (Rapamycin / CR) |
|---|---|
| Protein synthesis upregulated (S6K1 → ribosome biogenesis) | Protein synthesis reduced — cells catabolize and recycle damaged proteins |
| Autophagy suppressed (ULK1 phosphorylated and inhibited) | Autophagy induced — damaged organelles, protein aggregates, pathogens cleared |
| Senescent cell accumulation accelerated (mTOR drives SASP — senescence-associated secretory phenotype) | Senescent cell burden reduced; SASP inflammatory secretome reduced |
| Stem cell exhaustion — mTOR drives proliferative exhaustion of tissue stem cells | Stem cell quiescence preserved; regenerative capacity maintained |
| Immune aging (immunosenescence) — naive T cell output from thymus declines; mTOR drives T cell terminal differentiation | Thymic output improves; naive T cell frequency increases; vaccine responses enhanced (Mannick 2014) |
| Mitochondrial function — mTOR hyperactivation promotes mitochondrial fragmentation and ROS production | Mitophagy (mitochondrial quality control) upregulated; healthier mitochondrial network |
Joan Mannick (formerly Novartis, now resTORbio) conducted the most rigorous human trials of mTOR inhibition in aging biology. The 2018 Science Translational Medicine trial (N=264 adults ≥65) randomized participants to RTB101 (a selective TORC1 inhibitor), everolimus (a rapalog), combination, or placebo for 16 weeks entering the winter respiratory infection season. RTB101 10mg/day reduced respiratory infections by 31% vs placebo (p=0.03); combination RTB101 + everolimus reduced infections by 50%. Immune biomarkers: increased expression of antiviral genes, reduced proportion of exhausted T cells, improved influenza vaccine response. This trial is important because it demonstrates that mTOR inhibition in aged humans produces measurable immune rejuvenation — reduced infection rates are a hard clinical outcome, not just a biomarker.
The 2019 phase 3 trial of RTB101 alone (N=1,024, 20 weeks) for respiratory infection reduction in older adults did not meet its primary endpoint, though subgroups with asthma/COPD did benefit. The implication: intermittent dosing or combination rapalog protocols may be needed for full immune rejuvenation effects; single-agent TORC1 inhibition alone may be insufficient. Mannick's current work focuses on combination mTOR inhibitor protocols.
Rapamycin is an FDA-approved prescription immunosuppressant drug. At transplant doses (2–5mg/day continuous), it carries significant risks: increased infection susceptibility (especially fungal and viral), impaired wound healing, hyperlipidemia, thrombocytopenia, interstitial pneumonitis, and insulin resistance. These side effects are dose-dependent and continuous-dosing specific — the longevity protocols use intermittent low doses specifically to avoid immunosuppression while retaining autophagy and mTOR benefits. Key contraindications: active infection, pregnancy/breastfeeding, known hypersensitivity, strong CYP3A4 inhibitors (some antibiotics, azole antifungals — significantly increase rapamycin blood levels). Rapamycin requires a physician prescription and should not be used without physician oversight, periodic blood monitoring (CBC, lipids, metabolic panel, rapamycin trough levels), and an understanding of drug interactions. Off-label use for longevity is legal but requires informed consent and ongoing monitoring.
Disclaimer: This section describes protocols being used by some longevity physicians for healthy adults. This is not a recommendation. Rapamycin is a prescription drug with real risks. Do not use without a physician's supervision and periodic monitoring.
Most common longevity dosing protocol (intermittent): 5–6mg once weekly (some protocols use 3–5mg/week). The intermittent dosing rationale: weekly dosing allows mTORC1 inhibition for autophagy induction without the continuous mTORC2 suppression that drives immunosuppression and metabolic side effects. Trough levels with weekly dosing fall near zero by day 6–7, restoring immune function between doses. This is distinct from transplant dosing (daily continuous dosing targeting trough levels of 5–15 ng/mL).
Starting dose and monitoring: Many physicians start at 1–2mg/week and titrate up over 2–4 months. Monitor: complete blood count (watch for thrombocytopenia, leukopenia), lipid panel (rapamycin raises LDL and triglycerides in some patients — may need statin), fasting glucose and insulin (rapamycin can cause insulin resistance — monitor for new metabolic issues), and optionally rapamycin trough level at 24–48 hours post-dose to assess individual clearance variability (CYP3A4 and P-gp polymorphisms cause significant inter-individual pharmacokinetic variation).
Drug interactions requiring dose adjustment: Grapefruit juice and grapefruit (inhibit CYP3A4, significantly raise rapamycin levels — avoid completely); azole antifungals (fluconazole, itraconazole — potent CYP3A4 inhibitors; pause rapamycin during course); macrolide antibiotics (clarithromycin — moderate CYP3A4 inhibitor); rifampin (CYP3A4 inducer — dramatically reduces rapamycin levels). Take with food to reduce GI side effects; fat intake with the dose may increase absorption variability.
Who the longevity physician community considers appropriate candidates: Adults over 50 in good health with no active infection, no planned surgery (discontinue 4–6 weeks before surgery due to impaired wound healing), no active immunosuppression needs, not pregnant or planning pregnancy; BMI <35 (rapamycin-induced insulin resistance is more clinically significant in metabolically unhealthy individuals); no significant renal impairment.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.